Ophthalmic Business News

PHILADELPHIA — In this video from Building a Successful Practice – Pennsylvania, Emily Ast, Esq., said asking questions up front when negotiating physician contracts ensures physicians commit to only providing expected services.

Cimerli, a biosimilar interchangeable with Lucentis, will launch in the United States on Oct. 3, according to a press release from Coherus BioSciences.

Sight Sciences has completed enrollment in the SAHARA trial, which is evaluating the TearCare system to treat the signs and symptoms of dry eye disease, according to a press release.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Sean Ianchulev, MD, MPH.

Trukera Medical announced the launch of the ScoutPro osmolarity system, the first device unveiled under the company’s new name, according to a press release.

Between the loss of income and increases in medical care costs, disabling injuries suffered by high-income physicians can cause financial devastation that far exceeds that of their premature death.

The first patient has been enrolled in a two-stage phase 2 study of D-4517.2 for the treatment of wet age-related macular degeneration or diabetic macular edema, according to a press release from Ashvattha Therapeutics.

MONTEREY, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Kristen Nwanyanwu, MD, MBA, MHS, discusses her journey creating Eyeful LLC, a luxury case brand for ophthalmic lenses.

TearLab is changing its name to Trukera Medical.

The GATHER2 phase 3 clinical trial of Zimura for the treatment of geographic atrophy met its primary endpoint and demonstrated a favorable safety profile, according to a press release from Iveric Bio.